Wales experts back HIV prophlyaxis, ahead of key meetings
Cost-effectiveness bodies in Wales and Scotland to decide on Truvada in April.
Cost-effectiveness bodies in Wales and Scotland to decide on Truvada in April.
Speculation mounting that Pfizer and others could try for $90 bn plus merger
But GSK hit back with plans for two-drug regimen.
Companies aim to cut treatment time and side effects.
Gilead makes key hiring amid M&A rumours.
Ruling relates to infringement of patents held by Merck subsidiary
Large trial of HIV PrEP could lead to national programme
Court ruling paves way for decision on PrEP.
Two major biotech firms hit by investor disappointment